{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:55:09Z","timestamp":1790153709688,"version":"4.0.1"},"reference-count":37,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25055","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:08:31Z","timestamp":1766527711000},"page":"259-267","source":"Crossref","is-referenced-by-count":4,"title":["Development and biomarkers of CD20\/CD3 bispecific antibodies in diffuse large B-cell lymphoma"],"prefix":"10.3960","volume":"65","author":[{"given":"Chisako","family":"Iriyama","sequence":"first","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Crump M, Neelapu SS, Farooq U et al.<\/i> Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130: 1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Thieblemont C, Phillips T, Ghesquieres H et al.<\/i> Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023; 41: 2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Thieblemont C, Karimi YH, Ghesquieres H et al.<\/i> Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024; 38: 2653-2662.","DOI":"10.1038\/s41375-024-02410-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Dickinson MJ, Carlo-Stella C, Morschhauser F et al.<\/i> Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387: 2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bartlett NL, Assouline S, Giri P et al.<\/i> Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2023; 7: 4926-4935.","DOI":"10.1182\/bloodadvances.2022009260"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bannerji R, Arnason JE, Advani RH et al.<\/i> Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9: e327-e339.","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kim WS, Kim TM, Cho SG et al.<\/i> Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025; 6: 528-539.","DOI":"10.1038\/s43018-025-00921-6"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ennishi D, Takata K, B\u00e9guelin W et al.<\/i> Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019; 9: 546-563.","DOI":"10.1158\/2159-8290.CD-18-1090"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Pascual M, Mena-Varas M, Robles EF et al.<\/i> PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019; 133: 2401-2412.","DOI":"10.1182\/blood.2018889931"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bargou R, Leo E, Zugmaier G et al.<\/i> Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321: 974-977.","DOI":"10.1126\/science.1158545"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Sun LL, Ellerman D, Mathieu M et al.<\/i> Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7: 287ra70.","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Engelberts PJ, Hiemstra IH, de Jong B et al.<\/i> DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020; 52: 102625.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Bacac M, Colombetti S, Herter S et al.<\/i> CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. 2018; 24: 4785-4797.","DOI":"10.1158\/1078-0432.CCR-18-0455"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Rosenthal A, Munoz J, Jun M et al.<\/i> Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed\/refractory large B-cell lymphoma. J Hematol Oncol. 2024; 17: 69.","DOI":"10.1186\/s13045-024-01594-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Shumilov E, Wurm-Kuczera R, Kerkhoff A et al.<\/i> Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study. Blood Adv. 2025; 9: 3865-3877.","DOI":"10.1182\/bloodadvances.2024014903"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Brooks TR, Zabor EC, Bedelu Y et al.<\/i> Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025; 146: 2177-2188.","DOI":"10.1182\/blood.2025029117"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Abramson JS, Ku M, Hertzberg M et al.<\/i> Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024; 404: 1940-1954.","DOI":"10.1016\/S0140-6736(24)01774-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Brody JD, J\u00f8rgensen J, Belada D et al.<\/i> Epcoritamab plus GemOx in transplant-ineligible relapsed\/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025; 145: 1621-1631.","DOI":"10.1182\/blood.2024026830"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Budde LE, Olszewski AJ, Assouline S et al.<\/i> Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial. Nat Med. 2024; 30: 229-239.","DOI":"10.1038\/s41591-023-02726-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Crombie JL, Graff T, Falchi L et al.<\/i> Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024; 143: 1565-1575.","DOI":"10.1182\/blood.2023022432"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 van der Horst HJ, de Jonge AV, Hiemstra IH et al.<\/i> Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021; 11: 38.","DOI":"10.1038\/s41408-021-00430-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Chong EA, Penuel E, Napier EB et al.<\/i> Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025; 9: 696-703.","DOI":"10.1182\/bloodadvances.2024013640"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Crochet G, Iacoboni G, Couturier A et al.<\/i> Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood. 2024; 144: 334-338.","DOI":"10.1182\/blood.2024024526"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Shumilov E, Scholz JK, Seib M et al.<\/i> Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025; 9: 3955-3966.","DOI":"10.1182\/bloodadvances.2024015719"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Br\u00f6ske AE, Korfi K, Belousov A et al.<\/i> Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 2022; 6: 1025-1037.","DOI":"10.1182\/bloodadvances.2021005954"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Iacoboni G, S\u00e1nchez-Salinas MA, Rejeski K et al.<\/i> Efficacy and safety of bendamustine-containing bridging therapy in R\/R LBCL patients receiving CD19 CAR T-cells. HemaSphere. 2024; 8: e86.","DOI":"10.1002\/hem3.86"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Schuster SJ, Huw LY, Bolen CR et al.<\/i> Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas. Blood. 2024; 143: 822-832.","DOI":"10.1182\/blood.2023022348"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Bray JS, Thomas GR, Smith VM et al.<\/i> In vitro comparison of CD20xCD3 bispecific antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20. Br J Haematol. 2025; 206: 1350-1354.","DOI":"10.1111\/bjh.20033"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Brouwer-Visser J, Fiaschi N, Deering RP et al.<\/i> Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. J Immunother Cancer. 2024; 12: e008338.","DOI":"10.1136\/jitc-2023-008338"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Falchi L, Rahman J, Melendez L et al.<\/i> Intratumoral T-cell composition predicts epcoritamab-based treatment efficacy in B-cell non-Hodgkin lymphomas. medRxiv. 2024 [Preprint].","DOI":"10.1101\/2024.07.02.24309792"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Duell J, Leipold AM, Appenzeller S et al.<\/i> Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. Blood. 2024; 143: 685-696.","DOI":"10.1182\/blood.2023021672"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kawasaki N, Nishito Y, Yoshimura Y, Yoshiura S. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. Br J Haematol. 2022; 199: 245-255.","DOI":"10.1111\/bjh.18341"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 de Jonge AV, Csik\u00f3s T, Eken M et al.<\/i> Delineating MYC-mediated escape mechanisms from conventional and T cell-redirecting therapeutic antibodies. Int J Mol Sci. 2024; 25: 12094.","DOI":"10.3390\/ijms252212094"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Tumuluru S, Godfrey JK, Cooper A et al.<\/i> Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025; 145: 2460-2472.","DOI":"10.1182\/blood.2024025355"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Wright GW, Huang DW, Phelan JD et al.<\/i> A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020; 37: 551-568.e14.","DOI":"10.1016\/j.ccell.2020.03.015"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Raj SS, Fei T, Fried S et al.<\/i> An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med. 2025; 31: 1183-1194.","DOI":"10.1038\/s41591-025-03532-x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Rejeski K, Perez A, Sesques P et al.<\/i> CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood. 2021; 138: 2499-2513.","DOI":"10.1182\/blood.2020010543"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25055\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:55Z","timestamp":1766810515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25055\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25055","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25055"}}